Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Two research studies published in The New England Journal of Medicine found taking SSRIs (selective serotonin reuptake inhibitors), anti-depression drugs, during pregnancy did not significantly increase the overall risk for most birth defects.
Researchers at the University of Alberta have identified a "central command system" for pulmonary hypertension, a disease that currently has no cure and kills thousands each year.
Protected by its own nutrients and blood supply, a beating heart supported by an investigational organ preservation device was successfully transplanted into a 47-year-old man with congestive heart failure and pulmonary hypertension on Sunday, April 8.
BioMarin Pharmaceutical has announced that the first patient has initiated treatment in the Phase 2a clinical study of 6R-BH4 (sapropterin dihydrochloride) for the treatment of sickle cell disease (SCD).
African-American women have the highest mortality rate for idiopathic pulmonary arterial hypertension (IPAH), according to new research.
In a medical case of Jekyll and Hyde, carbon monoxide - the highly toxic gas emitted from auto exhausts and faulty heating systems - has proven effective in treating the symptoms of pulmonary arterial hypertension (PAH), an extremely debilitating condition that typically leads to right heart failure and eventual death.
Delivering nitric oxide to the lungs of premature, very-low-birth-weight infants during their second week of life improves their chances of surviving without chronic lung disease, according to a national study of nearly 600 babies.
As many as 3 percent of all pregnancies result in the birth of a baby with chromosomal anomalies like Down syndrome or structural anomalies such as congenital heart disease.
Measuring levels of a hormone called brain natriuretic peptide in individuals with serious lung disease can predict the presence of pulmonary hypertension and a patient's potential death or survival, regardless of clinical severity or the cause of illness.
The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).
Researchers have found that a simple test for an enzyme called LDH may have significant importance for determining major risk factors in adults with sickle cell disease.
A University of California, San Diego (UCSD) School of Medicine collaborative study with Boston University's Slone Epidemiology Center found an increased risk of persistent pulmonary hypertension (PPHN) in newborns of mothers who used certain commonly prescribed antidepressants in late pregnancy.
According to the results of a new study by researchers at Johns Hopkins, Viagra, a drug used to treat erectile dysfunction (ED) in millions of men, reduces the stimulatory effects of hormonal stress on the heart by half.
Sildenafil citrate (Viagra), a drug used to treat erectile dysfunction (ED) in millions of men, reduces the stimulatory effects of hormonal stress on the heart by half, according to results of a new study by researchers at Johns Hopkins.
Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension
What's more, the team demonstrated through studies in people and animals that inhalation of a 'souped up' form of nitric oxide, which targets red blood cells, reverses the blood abnormality to restore normal lung pressure.
German researchers have reported on the impact of Viagra on pulmonary hypertension at the Frontiers of Vascular Medicine Conference at Monash University this week.
The results of an international clinical trial led by Duke University Medical Center researchers has shown that a new drug is not a suitable replacement for protamine, a drug that has been used for more than 40 years after coronary artery bypass surgery to return thinned blood to its normal state.
A new study led by a researcher at Children's Hospital & Research Center at Oakland is the first to find that an amino acid deficiency in sickle cell disease is the result of hemolysis, a process where red blood cells rupture and release their contents into the blood stream. Low availability of the amino acid arginine is associated with lung disease and death in adult sickle cell patients.
A University of Alberta research team has discovered important new information they hope will lead to more effective treatments for pulmonary arterial hypertension (PAH)--a deadly form of high blood pressure in the pulmonary arteries caused by uncontrolled cell growth.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.